Home › Non-Small Cell Lung Cancer › North Carolina › Greenville
Non-Small Cell Lung Cancer clinical trials in Greenville, NC
3 studies for Non-Small Cell Lung Cancer are looking for participants at sites in and around Greenville (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RecruitingPhase 3
- Brody School of Medicine at East Carolina University, Greenville
- ECU Health Medical Center, Greenville
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RecruitingPhase 3
- Research Site, Greenville
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RecruitingPhase 3
- East Carolina University, Greenville
Non-Small Cell Lung Cancer trials in other cities
- Houston, TX145 studies
- New York City, NY121 studies
- Arlington, VA104 studies
- Nashville, TN97 studies
- Boston, MA90 studies
- Los Angeles, CA87 studies
- St. Louis, MO73 studies
- Chicago, IL61 studies
- Baltimore, MD60 studies
- San Antonio, TX59 studies
- Columbus, OH57 studies
- Washington, DC55 studies
Other studies in Greenville
- Acute Myeloid Leukemia10 studies
- Sickle Cell Disease9 studies
- Idiopathic Thrombocytopenic Purpura6 studies
- Heart Failure6 studies
- Chronic Lymphocytic Leukemia5 studies
- Burkitt Lymphoma5 studies
- Obesity5 studies
- Type 2 Diabetes5 studies
- Blood Disorders5 studies
- Cancer (all types)4 studies
- Autoimmune Diseases4 studies
- Myeloproliferative Neoplasms4 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.